Hi all—
The US Preventive Services Task Force (USPSTF) is in the news this week following the firing of Task Force leaders, so we wanted to share a quick, clear snapshot of where things stand and what you might need as consumers, leaders, and communicators in this space.
Bottom line up front: nothing has changed in terms of recommendations or coverage at this time. People can still access preventative services, like cancer screening, without out-of-pocket costs. But things seem to be shifting in the background.
What is USPSTF?
An independent panel of experts in preventive medicine and primary care that develops evidence-based recommendations on preventive services like screenings, counseling, or medications. Here is an explainer.
The impacts of changes to USPSTF recommendations are far more complex than those of the ACIP changes. In addition to the breadth of what USPSTF covers (90 recommendations!), there isn’t an alternative single source of unbiased, neutral evidence that organizations can point to, aside from updated recommendations.
What has already happened? A quiet shuffling.
Since March 2025, the task force has been inactive. The Agency for Healthcare Research and Quality (AHRQ) has canceled the task force’s regularly scheduled meetings (typically 3 per year), thereby delaying the consideration and advancement of preventive medical recommendations on a variety of topics for which the evidence reviews are complete, including cervical cancer, perinatal depression, unhealthy alcohol use among adolescents and adults, and medication to prevent falls and fractures.
Last summer, Secretary RFK Jr. planned to remove all 16 USPSTF members, calling them “too woke.” The announcement drew immediate pushback from the AMA, five major physician associations, and dozens of former task force members.
In late April 2026, during congressional testimony, the Secretary said he intends to “reform” the task force, bring in new members, increase meeting frequency, and introduce transparency, criticizing it as “lackadaisical.”
On April 22nd, HHS published a Federal Register notice soliciting nominees for new USPSTF members, seeking candidates with a wide range of specialties, including expertise in health economics - a notable addition to the traditional clinical profile of task force members. Nominations are due by May 23, 2026, with new members expected to begin serving in June 2026.
Yesterday, (May 20, 2026), two top USPSTF leaders (Chair and Vice Chair) were fired, an indication the Administration is moving on new appointees including the leadership of the body. For more on the operations of the Task Force, including the role of the leadership positions, take a deep dive via the USPSTF Structure and Process Manual.
What could happen next?
It is possible that activities will resume soon under a new advisory committee picked by RFK Jr. There are a few ways this could play out:
No updates: Recommendations remain without updates despite new evidence (aka some recommendations are “stale”) (high probability / moderate risk of harm)
Downgrades: Downgrade of existing A and B recommendations without supporting evidence (medium probability /high risk of harm)
Upgrades: New/upgraded A or B recommendations without supporting evidence (low probability/ low risk of harm)
Other changes to the recommendations: Removal of population-specific or equity language from recommendations (medium probability, moderate risk of harm)
Here is an expanded, iterative implications table outlining potential impacts across scenarios and audiences. As with the tables we created for ACIP changes, this will be updated regularly with new information, so check back regularly and reach out if we’re missing something important for a specific sector.
Have questions?
Here is an FAQ that addresses the most common questions we’re hearing
Talking points
If you’re engaging externally or fielding questions, here are a few key points to keep in mind:
Nothing has changed regarding recommendations or coverage at this time. People can still access preventative services, like cancer screening, without out-of-pocket costs.
Emphasize what is known vs. unknown and that coverage and clinical guidance haven’t changed
Reinforce your organization’s commitment to transparency and evidence-based decision-making
We’ll continue to monitor and share updates as things evolve. In the meantime, feel free to reach out if you have questions that aren’t covered here.
Best,
TEC and CHC (Common Health Coalition)
